# The Efficacy and Safety of Tirofiban Enhanced Antiplatelet Therapy in the Treatment of Ruptured Intracranial Aneurysms With Stent

Study · id `cardio:ct-nct07818083` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07818083](<https://clinicaltrials.gov/study/NCT07818083>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07818083

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 622 participants.

## Technical summary

Registry record NCT07818083. Randomized; triple masking; primary purpose treatment. Start 2026-09-01 (anticipated); primary completion 2028-09-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 622 participants (planned count; ClinicalTrials.gov record NCT07818083, source copy `cardio:ctgov-nct07818083-2026-09-14`, retrieved 2026-10-31)
- Planned start: 2026-09-01 (anticipated) (ClinicalTrials.gov record NCT07818083, source copy `cardio:ctgov-nct07818083-2026-09-14`, retrieved 2026-10-31)
- Primary completion: 2028-09-30 (anticipated) (ClinicalTrials.gov record NCT07818083, source copy `cardio:ctgov-nct07818083-2026-09-14`, retrieved 2026-10-31)
- Completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT07818083, source copy `cardio:ctgov-nct07818083-2026-09-14`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07818083-2026-09-14`, retrieved 2026-10-31)

## The registry's words

- Brief title: The Efficacy and Safety of Tirofiban Enhanced Antiplatelet Therapy in the Treatment of Ruptured Intracranial Aneurysms With Stent
- Acronym: TEARIAS
- Condition: Ruptured Intracranial Aneurysms
- Condition: Subarachnoid Hemorrhage, Aneurysmal
- Intervention (Drug): Tirofiban+Oral Dual Antiplatelet Therapy
- Intervention (Drug): Dual Antiplatelet Therapy plus Normal Saline
- Lead sponsor: First Affiliated Hospital of Fujian Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Subarachnoid hemorrhage (`cardio:subarachnoid-hemorrhage`)
- Registry lists this organization as the lead sponsor: First Affiliated Hospital of Fujian Medical University (`cardio:org-first-affiliated-hospital-of-fujian-medical-university`)

## Provenance

Content hash: 76cfe03d82f87f2629f80afff125dfd66eab1b4de0fbee31524bae4a42aa5dea
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
